東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Devalued and distrusted = can the ph...

LaMattina, John L.

FindBook

Google Book

Amazon

博客來

Devalued and distrusted = can the pharmaceutical industry restore its broken image? /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Devalued and distrusted/ John L. LaMattina, PhD.
其他題名:	can the pharmaceutical industry restore its broken image? /
作者:	LaMattina, John L.
出版者:	Hoboken, New Jersey :Wiley, : [2013],
面頁冊數:	1 online resource (ix, 125 pages)
內容註:	1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.
標題:	Pharmaceutical industry - Corrupt practices. -
電子資源:	http://onlinelibrary.wiley.com/book/10.1002/9781118511329

Devalued and distrusted = can the pharmaceutical industry restore its broken image? /
LaMattina, John L.

Devalued and distrustedcan the pharmaceutical industry restore its broken image? /[electronic resource] :John L. LaMattina, PhD. - Hoboken, New Jersey :Wiley,[2013] - 1 online resource (ix, 125 pages)

Includes bibliographical references and index.

1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.

License restrictions may limit access.

"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--

Publisher. No.: EB00063788Recorded BooksSubjects--Topical Terms:

2148333
Pharmaceutical industry
--Corrupt practices.

LC Class. No.: HD9665.5 / .L36 2013eb

Dewey Class. No.: 338.4/76151

Devalued and distrusted = can the pharmaceutical industry restore its broken image? /
LDR:02441cmm a2200385Ma 4500 001 2003224
003 OCoLC
005 20151013061237.0
006 m o d
007 cr |||||||||||
008 151223s2013 nju ob 001 0 eng d
020 $z 9781118487471 (pbk.)
020 $a 1118487478 (pbk.)
020 $a 9781283917421 (MyiLibrary)
020 $a 1283917424 (MyiLibrary)
020 $a 9781118511251 (electronic bk.)
020 $a 1118511255 (electronic bk.)
020 $a 9781118511299 (electronic bk.)
020 $a 1118511298 (electronic bk.)
020 $a 9781118511329 (electronic bk.)
020 $a 1118511328 (electronic bk.)
028 0 1 $a EB00063788 $b Recorded Books
035 $a (OCoLC)831464032 $z (OCoLC)823389919 $z (OCoLC)829353805 $z (OCoLC)864914474 $z (OCoLC)880910023
035 $a ocn831464032
040 $a AZU $b eng $c AZU $d OCLCO $d CCO $d IDEBK $d E7B $d GPM $d OCLCF $d YDXCP $d RECBK $d MHW $d EBLCP $d N $d DG1 $d TEFOD $d DEBSZ $d UKDOC $d LRU $d GGVRL $d OCLCQ $d AU@ $d CDX $d DEBBG $d TEFOD
050 4 $a HD9665.5 $b .L36 2013eb
082 0 4 $a 338.4/76151 $2 23
100 1 $a LaMattina, John L. $3 1965694
245 1 0 $a Devalued and distrusted $h [electronic resource] : $b can the pharmaceutical industry restore its broken image? / $c John L. LaMattina, PhD.
260 $a Hoboken, New Jersey : $b Wiley, $c [2013]
300 $a 1 online resource (ix, 125 pages)
504 $a Includes bibliographical references and index.
505 0 $a 1. The four secrets the drug companies don't want you to know -- 2. What has happened to R & D productivity? -- 3. Key therapeutic areas for improving health -- 4. Improving R & D output -- 5. Restoring pharma's image -- 6. Final thoughts.
506 $a License restrictions may limit access.
520 $a "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R & D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- $c Provided by publisher.
588 0 $a Print version record.
650 0 $a Pharmaceutical industry $x Corrupt practices. $3 2148333
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9781118511329